EGFR and lung adenocarcinoma: In the current study, Asian patients with positive exon 19 EGFR-mutant lung adenocarcinoma and newly diagnosed brain metastases who initially received peroral administration of 150 mg/d erlotinib or 250 mg/d gefitinib were followed for a mean of 36 months, and the most important finding was that erlotinib was associated with a significantly longer OS and more prolonged PFS than gefitinib.